AVEO Pharmaceuticals Inc. (AVEO)

1.00
0.02 2.40
NASDAQ : Health Technology
Prev Close 0.98
Open 1.04
Day Low/High 0.99 / 1.05
52 Wk Low/High 0.49 / 3.59
Volume 2.22M
Avg Volume 3.05M
Exchange NASDAQ
Shares Outstanding 160.74M
Market Cap 153.96M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AVEO Reports Second Quarter 2019 Financial Results And Provides Business Update

AVEO Reports Second Quarter 2019 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update.

First Week Of AVEO September 20th Options Trading

First Week Of AVEO September 20th Options Trading

Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the September 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new September 20th contracts and identified the following call contract of particular interest.

Interesting AVEO Call Options For August 16th

Interesting AVEO Call Options For August 16th

Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new August 16th contracts and identified the following call contract of particular interest.

AVEO Oncology To Present At The 2019 BIO International Convention

AVEO Oncology To Present At The 2019 BIO International Convention

AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.

AVEO Oncology Announces Presentations At The 2019 ASCO Annual Meeting

AVEO Oncology Announces Presentations At The 2019 ASCO Annual Meeting

AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.

AVEO Reports First Quarter 2019 Financial Results And Provides Business Update

AVEO Reports First Quarter 2019 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.

AVEO Oncology To Participate In The 5th Annual SunTrust Robinson Humphrey Life Sciences Summit

AVEO Oncology To Participate In The 5th Annual SunTrust Robinson Humphrey Life Sciences Summit

AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019.

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization Of FOTIVDA® In Spain

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization Of FOTIVDA® In Spain

AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Aveo Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline -AVEO

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Aveo Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline -AVEO

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering

AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) ("AVEO" or the "Company"), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of its...

Noteworthy Tuesday Option Activity: AVEO, CARS, WBT

Noteworthy Tuesday Option Activity: AVEO, CARS, WBT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AVEO Pharmaceuticals Inc , where a total of 51,729 contracts have traded so far, representing approximately 5.2 million underlying shares. That amounts to about 78% of AVEO's average daily trading volume over the past month of 6.6 million shares.

AVEO Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

AVEO Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.

AVEO Reports Full Year 2018 Financial Results And Provides Business Update

AVEO Reports Full Year 2018 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2018 and provided a business update.

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of AVEO Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of AVEO Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of AVEO Pharmaceuticals, Inc.

AVEO INVESTOR ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors Of Important Deadline In Securities Class Action Lawsuit - AVEO

AVEO INVESTOR ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors Of Important Deadline In Securities Class Action Lawsuit - AVEO

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc.

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTOR ACTION ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Appointment Of Gregory T. Mayes To Its Board Of Directors

AVEO Oncology Announces Appointment Of Gregory T. Mayes To Its Board Of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Gregory T. Mayes to its Board of Directors.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc.

AVEO Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

AVEO Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.

Figure 2: Progression-Free Survival Per IRC In Patients Receiving Prior IO (Subgroup Analysis) (Graphic: Business Wire)

Figure 2: Progression-Free Survival Per IRC In Patients Receiving Prior IO (Subgroup Analysis) (Graphic: Business Wire)

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).

AVEO Oncology Announces NDA Timing Update

AVEO Oncology Announces NDA Timing Update

AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.

First Week Of February 15th Options Trading For AVEO Pharmaceuticals (AVEO)

First Week Of February 15th Options Trading For AVEO Pharmaceuticals (AVEO)

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new February 15th contracts and identified the following call contract of particular interest.

AVEO Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.

AVEO Oncology To Present TIVO-3 Data At The 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology To Present TIVO-3 Data At The 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American...

Here's a Handful of Small Biotechs Where Insiders Are Buying

Here's a Handful of Small Biotechs Where Insiders Are Buying

Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration With AstraZeneca

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration With AstraZeneca

AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI ® (durvalumab), a human monoclonal antibody directed against programmed...

TheStreet Quant Rating: D- (Sell)